Wyeth Pharmaceuticals received approval from the FDA for Tygacil (tigecycline) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by susceptible strains of indicated pathogens. The drug was first approved by the FDA in 2005 for the treatment of complicated intra-abdominal infections (cIAI) and complicated skin and skin structure infections (cSSSI) in adults. CABP infects an estimated 4.5 million people each year.

“The approval of this new indication is timely. Antibiotic resistance continues to grow and new antimicrobials are needed,” says Joseph Camardo, M.D., senior vice president, Global Medical Affairs, Wyeth Pharmaceuticals. “The approval of Tygacil for CABP is an important milestone in Wyeth’s commitment to exploring new treatment options in the anti-infective therapeutic area.”